Is France falling behind in the deployment of its digital medical devices compared to its neighbors?
As of mid-February 2023, of the 42 DIGAs listed, 16 DIGAs have been admitted and can be consulted by patients. A classification by pathological group or brand name of the devices included in this program is emerging. A pricing model which is structured with prices varying from €119 to €952 per quarter and the submission of manufacturers to a fixed maximum amount varying according to the pathology group to which the device belongs, the DIGA status (permanently admitted or trial) and the number of activation codes delivered.
| STATUT DU DIGA : Admission à l’essai | STATUT DU DIGA : Admission permanentes |
2 000 codes | 80% du montant max | Montant max (pas appliqué la première année d’inclusion) |
10 000 codes | 60% du montant max | 75% du montant max |
A system very favorable to digital DMs:
- With patients better monitored and actors in their health (a very accessible system);
- An adaptation of the system to the solutions presented;
- Stable and fairly high redemption prices with low degressivity.
A few points to consolidate:
- 26 DIGAs with no evidence of efficacy after one year are still in the trial period with temporary coverage;
- An increase in the average prices for the DIGAs under test is observed, whereas the "permanent" DiGAs have a constant or slightly decreasing price.
Wouldn't it be time for France to rely more on this success to consolidate the launch of PECAN to finally enter the digital health race?